Leiomyosarcoma

News alerts, weekly reports and conference planners

Related cancers:

HR positive	Leiomyosarcoma	HR positive	Leiomyosarcoma	nivolumab + talimogene laherparepvec Sensitive: C3 – Early Trials ASGCT 2023 - 3 weeks (New C3) nivolumab + talimogene laherparepvec Sensitive : C3 ASGCT 2023 - 3wk	nivolumab + talimogene laherparepvec Sensitive: C3 – Early Trials ASGCT 2023 - 3 weeks nivolumab + talimogene laherparepvec Sensitive : C3 ASGCT 2023 - 3 weeks - (New C3)
No biomarker	Leiomyosarcoma	No biomarker	Leiomyosarcoma	trabectedin Sensitive: A1 - Approval trabectedin Sensitive : A1	trabectedin Sensitive: A1 - Approval trabectedin Sensitive : A1
No biomarker	Uterine Corpus Leiomyosarcoma	No biomarker	Uterine Corpus Leiomyosarcoma	pazopanib Sensitive: A2 - Guideline pazopanib Sensitive : A2	pazopanib Sensitive: A2 - Guideline pazopanib Sensitive : A2
ER positive	Uterine Corpus Leiomyosarcoma	ER positive	Uterine Corpus Leiomyosarcoma	Aromatase inhibitor Sensitive: A2 - Guideline Aromatase inhibitor Sensitive : A2	Aromatase inhibitor Sensitive: A2 - Guideline Aromatase inhibitor Sensitive : A2
PGR positive	Uterine Corpus Leiomyosarcoma	PGR positive	Uterine Corpus Leiomyosarcoma	Aromatase inhibitor Sensitive: A2 - Guideline Aromatase inhibitor Sensitive : A2	Aromatase inhibitor Sensitive: A2 - Guideline Aromatase inhibitor Sensitive : A2
No biomarker	Leiomyosarcoma	No biomarker	Leiomyosarcoma	eribulin mesylate Sensitive: A2 - Guideline eribulin mesylate Sensitive : A2	eribulin mesylate Sensitive: A2 - Guideline eribulin mesylate Sensitive : A2
PGR positive	Uterine Corpus Leiomyosarcoma	PGR positive	Uterine Corpus Leiomyosarcoma	medroxyprogesterone Sensitive: A2 - Guideline medroxyprogesterone Sensitive : A2	medroxyprogesterone Sensitive: A2 - Guideline medroxyprogesterone Sensitive : A2
ER positive	Uterine Corpus Leiomyosarcoma	ER positive	Uterine Corpus Leiomyosarcoma	medroxyprogesterone Sensitive: A2 - Guideline medroxyprogesterone Sensitive : A2	medroxyprogesterone Sensitive: A2 - Guideline medroxyprogesterone Sensitive : A2
PGR positive	Uterine Corpus Leiomyosarcoma	PGR positive	Uterine Corpus Leiomyosarcoma	megestrol Sensitive: A2 - Guideline megestrol Sensitive : A2	megestrol Sensitive: A2 - Guideline megestrol Sensitive : A2
ER positive	Uterine Corpus Leiomyosarcoma	ER positive	Uterine Corpus Leiomyosarcoma	megestrol Sensitive: A2 - Guideline megestrol Sensitive : A2	megestrol Sensitive: A2 - Guideline megestrol Sensitive : A2
No biomarker	Leiomyosarcoma	No biomarker	Leiomyosarcoma	doxorubicin hydrochloride + dacarbazine Sensitive: A2 - Guideline doxorubicin hydrochloride + dacarbazine Sensitive : A2	doxorubicin hydrochloride + dacarbazine Sensitive: A2 - Guideline doxorubicin hydrochloride + dacarbazine Sensitive : A2
No biomarker	Leiomyosarcoma	No biomarker	Leiomyosarcoma	PTC596 Sensitive: B - Late Trials PTC596 Sensitive : B	PTC596 Sensitive: B - Late Trials PTC596 Sensitive : B
AKT1 E17K	Uterine Corpus Leiomyosarcoma	AKT1 E17K	Uterine Corpus Leiomyosarcoma	AZD5363 Sensitive: C3 – Early Trials AZD5363 Sensitive : C3	AZD5363 Sensitive: C3 – Early Trials AZD5363 Sensitive : C3
Chr amplification(4)(q22.1)	Leiomyosarcoma	Chr amplification(4)(q22.1)	Leiomyosarcoma	eribulin mesylate Resistant: C3 – Early Trials eribulin mesylate Resistant : C3	eribulin mesylate Resistant: C3 – Early Trials eribulin mesylate Resistant : C3
Chr del(3)(q14.2)	Leiomyosarcoma	Chr del(3)(q14.2)	Leiomyosarcoma	eribulin mesylate Resistant: C3 – Early Trials eribulin mesylate Resistant : C3	eribulin mesylate Resistant: C3 – Early Trials eribulin mesylate Resistant : C3
Chr del(11)(q25)	Leiomyosarcoma	Chr del(11)(q25)	Leiomyosarcoma	eribulin mesylate Resistant: C3 – Early Trials eribulin mesylate Resistant : C3	eribulin mesylate Resistant: C3 – Early Trials eribulin mesylate Resistant : C3
Chr del(2)(q14.1)	Leiomyosarcoma	Chr del(2)(q14.1)	Leiomyosarcoma	eribulin mesylate Resistant: C3 – Early Trials eribulin mesylate Resistant : C3	eribulin mesylate Resistant: C3 – Early Trials eribulin mesylate Resistant : C3
Chr del(2)(p12)	Leiomyosarcoma	Chr del(2)(p12)	Leiomyosarcoma	eribulin mesylate Sensitive: C3 – Early Trials eribulin mesylate Sensitive : C3	eribulin mesylate Sensitive: C3 – Early Trials eribulin mesylate Sensitive : C3
Chr del(1)(q44)	Leiomyosarcoma	Chr del(1)(q44)	Leiomyosarcoma	eribulin mesylate Resistant: C3 – Early Trials eribulin mesylate Resistant : C3	eribulin mesylate Resistant: C3 – Early Trials eribulin mesylate Resistant : C3
Chr amplification(8)(q13.2)	Leiomyosarcoma	Chr amplification(8)(q13.2)	Leiomyosarcoma	eribulin mesylate Resistant: C3 – Early Trials eribulin mesylate Resistant : C3	eribulin mesylate Resistant: C3 – Early Trials eribulin mesylate Resistant : C3
Chr amplification(8)(q22.2)	Leiomyosarcoma	Chr amplification(8)(q22.2)	Leiomyosarcoma	eribulin mesylate Resistant: C3 – Early Trials eribulin mesylate Resistant : C3	eribulin mesylate Resistant: C3 – Early Trials eribulin mesylate Resistant : C3
Chr amplification(13)(q13.3)	Leiomyosarcoma	Chr amplification(13)(q13.3)	Leiomyosarcoma	eribulin mesylate Resistant: C3 – Early Trials eribulin mesylate Resistant : C3	eribulin mesylate Resistant: C3 – Early Trials eribulin mesylate Resistant : C3
Chr amplification(20)(p12.2)	Leiomyosarcoma	Chr amplification(20)(p12.2)	Leiomyosarcoma	eribulin mesylate Resistant: C3 – Early Trials eribulin mesylate Resistant : C3	eribulin mesylate Resistant: C3 – Early Trials eribulin mesylate Resistant : C3
Chr amplification(4)(q26)	Leiomyosarcoma	Chr amplification(4)(q26)	Leiomyosarcoma	eribulin mesylate Resistant: C3 – Early Trials eribulin mesylate Resistant : C3	eribulin mesylate Resistant: C3 – Early Trials eribulin mesylate Resistant : C3
ATRX mutation	Leiomyosarcoma	ATRX mutation	Leiomyosarcoma	eribulin mesylate Resistant: C3 – Early Trials eribulin mesylate Resistant : C3	eribulin mesylate Resistant: C3 – Early Trials eribulin mesylate Resistant : C3
TP53 mutation	Leiomyosarcoma	TP53 mutation	Leiomyosarcoma	eribulin mesylate Sensitive: C3 – Early Trials eribulin mesylate Sensitive : C3	eribulin mesylate Sensitive: C3 – Early Trials eribulin mesylate Sensitive : C3
ATRX mutation	Leiomyosarcoma	ATRX mutation	Leiomyosarcoma	dacarbazine Resistant: C3 – Early Trials dacarbazine Resistant : C3	dacarbazine Resistant: C3 – Early Trials dacarbazine Resistant : C3
TP53 mutation	Leiomyosarcoma	TP53 mutation	Leiomyosarcoma	dacarbazine Resistant: C3 – Early Trials dacarbazine Resistant : C3	dacarbazine Resistant: C3 – Early Trials dacarbazine Resistant : C3
CD70 expression	Uterine Corpus Leiomyosarcoma	CD70 expression	Uterine Corpus Leiomyosarcoma	ARX305 Sensitive: C3 – Early Trials ARX305 Sensitive : C3	ARX305 Sensitive: C3 – Early Trials ARX305 Sensitive : C3
AKT1 mutation + mTOR mutation	Leiomyosarcoma	AKT1 mutation + mTOR mutation	Leiomyosarcoma	CB-228 Sensitive: C3 – Early Trials CB-228 Sensitive : C3	CB-228 Sensitive: C3 – Early Trials CB-228 Sensitive : C3
TMB-H	Leiomyosarcoma	TMB-H	Leiomyosarcoma	nivolumab + ipilimumab Sensitive: C3 – Early Trials nivolumab + ipilimumab Sensitive : C3	nivolumab + ipilimumab Sensitive: C3 – Early Trials nivolumab + ipilimumab Sensitive : C3
ER positive + PGR positive	Uterine Corpus Leiomyosarcoma	ER positive + PGR positive	Uterine Corpus Leiomyosarcoma	anastrozole Sensitive: C3 – Early Trials anastrozole Sensitive : C3	anastrozole Sensitive: C3 – Early Trials anastrozole Sensitive : C3
PGR positive	Uterine Corpus Leiomyosarcoma	PGR positive	Uterine Corpus Leiomyosarcoma	anastrozole Sensitive: C3 – Early Trials anastrozole Sensitive : C3	anastrozole Sensitive: C3 – Early Trials anastrozole Sensitive : C3

Leiomyosarcoma

Associations(53)

Associations
(53)